AIM ImmunoTech Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über AIM ImmunoTech Inc Unternehmen

AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

AIM ImmunoTech Inc Informationen



BörsenkürzelAIM

Name des UnternehmensAIM ImmunoTech Inc

IPO-datumJul 12, 1996

CEOEquels (Thomas K)

Anzahl der mitarbeiter21

WertpapierartOrdinary Share

GeschäftsjahresendeJul 12

Addresse2117 Sw Highway 484

StadtOCALA

BörseNASDAQ OMX – NASDAQ Basic Amex

LandUnited States of America

Postleitzahl32801

Telefon13524487797

Websitehttps://aimimmuno.com/

BörsenkürzelAIM

IPO-datumJul 12, 1996

CEOEquels (Thomas K)

Führungskräfte von AIM ImmunoTech Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Thomas K. Equels, Esq., J.D.

President, Chief Executive Officer, Executive Vice Chairman of the Board

38.91K

-15.00%

Dr. William M. Mitchell, M.D., Ph.D.

Independent Chairman of the Board

5.22K

-3.00%

Ms. Nancy K. Bryan

Independent Director

2.92K

-1.00%

Mr. David I. Chemerow

Independent Director

642.00

-1.00%

Mr. Robert (Rob) Dickey, IV

Chief Financial Officer

--

Mr. Peter W. Rodino, III

Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary

--

Ms. Jenene Thomas

Investor Relations

--

Mr. Ted D. Kellner

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Thomas K. Equels, Esq., J.D.

President, Chief Executive Officer, Executive Vice Chairman of the Board

38.91K

-15.00%

Dr. William M. Mitchell, M.D., Ph.D.

Independent Chairman of the Board

5.22K

-3.00%

Ms. Nancy K. Bryan

Independent Director

2.92K

-1.00%

Mr. David I. Chemerow

Independent Director

642.00

-1.00%

Mr. Robert (Rob) Dickey, IV

Chief Financial Officer

--

Mr. Peter W. Rodino, III

Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary

--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach Geschäftsbereich

Nach Region

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Sun, Nov 16

Aktionäre

Aktionärstypen

Aktionäre

Anteil

DRW Securities, LLC

1.52%

Equels (Thomas K)

1.36%

Kellner (Theodore D)

1.31%

Sabby Management, LLC

1.01%

The Vanguard Group, Inc.

0.61%

Andere

94.19%

Aktionäre

Anteil

DRW Securities, LLC

1.52%

Equels (Thomas K)

1.36%

Kellner (Theodore D)

1.31%

Sabby Management, LLC

1.01%

The Vanguard Group, Inc.

0.61%

Andere

94.19%

Aktionärstypen

Aktionäre

Anteil

Individual Investor

3.86%

Investment Advisor

2.18%

Investment Advisor/Hedge Fund

1.58%

Andere

92.38%

Institutionelle Beteiligung



Aktualisiert: Mon, Dec 8

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

56

107.25K

2.64%

--

2025Q3

59

107.25K

2.79%

+95.13K

2025Q2

58

12.12K

12.55%

-36.20K

2025Q1

67

48.31K

13.00%

-45.65K

2024Q4

64

46.48K

14.87%

-43.65K

2024Q3

61

90.13K

15.18%

+5.69K

2024Q2

61

84.44K

8.12%

+43.50K

2024Q1

64

40.95K

9.51%

-6.49K

2023Q4

65

41.55K

9.71%

-1.72K

2023Q3

69

43.37K

10.32%

-1.62K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

DRW Securities, LLC

43.29K

1.52%

+43.29K

--

Sep 30, 2025

Equels (Thomas K)

38.87K

1.36%

-15.00

-0.04%

Oct 24, 2025

Kellner (Theodore D)

37.20K

1.3%

+17.51K

+88.91%

Oct 24, 2025

Sabby Management, LLC

28.86K

1.01%

+28.86K

--

Sep 30, 2025

The Vanguard Group, Inc.

17.50K

0.61%

+17.50K

--

Sep 30, 2025

Deutsch (Todd A)

17.16K

0.6%

--

Dec 19, 2024

Geode Capital Management, L.L.C.

16.19K

0.57%

+16.19K

--

Sep 30, 2025

Mitchell (William M)

5.22K

0.18%

-4.00

-0.08%

Oct 24, 2025

Rodino (Peter W III)

4.01K

0.14%

-7.00

-0.17%

Oct 24, 2025

Appelrouth (Stewart L.)

3.89K

0.14%

+670.00

+20.82%

Dec 31, 2024

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

iShares Core S&P Total U.S. Stock Market ETF

0%

iShares Core S&P Total U.S. Stock Market ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Mar 03, 2025

Merger

100→1

Datum

Ex-Dividendentag

Art

Verhältnis

Mar 03, 2025

Merger

100→1